Covid-19 roundup: In­ovio nabs $3 mil­lion and a de­vel­op­ment part­ner for its vac­cine that's still on par­tial hold; Slaoui pro­pos­es halv­ing Mod­er­na vac­cine dos­es as dis­tri­b­u­tion lags

With its vac­cine can­di­date fi­nal­ly in Phase II, In­ovio is bag­ging $3 mil­lion in a part­ner­ship deal with Ad­vac­cine Bio­phar­ma­ceu­ti­cals Suzhou to de­vel­op and com­mer­cial­ize the can­di­date in Greater Chi­na.

Ad­vac­cine and In­ovio shook hands on a deal for ex­clu­sive rights to de­vel­op, man­u­fac­ture and com­mer­cial­ize the can­di­date, INO-4800, in Main­land Chi­na, Hong Kong, Macao and Tai­wan. In ad­di­tion to $3 mil­lion up­front, Ad­vac­cine is sweet­en­ing the deal with up to $108 mil­lion in mile­stone pay­ments. In re­turn, it stands to earn a “high sin­gle-dig­it per­cent­age” of an­nu­al net sales in each re­gion with­in Greater Chi­na. The com­pa­ny is al­so li­cens­ing its plas­mid man­u­fac­tur­ing process to In­ovio, with the right to sub­li­cense to In­ovio’s man­u­fac­tur­ing part­ners.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN